“青盲一号方”对实验性视神经损伤后视网膜神经节细胞的影响

外伤性视神经病变是重要的致盲眼病，对视功能危害极大，目前尚无公认有效的治疗方案，阻断或延缓原发性和/或继发性RGCs损伤的视神经保护是目前的研究重点。“青盲一号方”是由韦氏眼科第四代传人韦企平教授总结前辈经验所创制，已在临床应用数十年，疗效确切。目前，“青盲一号方”已获得国家专利（专利号：2014.1.0225390.2）。为更好地继承和发扬名老中医的学术经验，本研究将“青盲一号方”应用于实验性损伤的RGCs细胞和大鼠，对药物干预下的RGCs细胞形态学、组织病理学以及大鼠的视功能等指标变化进行综合评价。用现代实验学方法研究临床验方“青盲一号方”，为临床用药提供新的理论指导，同时为进一步探究“青盲一号方”复方的作用机制打下坚实的研究基础，为视神经损伤探索新的治疗手段。

Traumatic optic neuropathy is severe blinding eye disease, with great visual function damage. There is no generally accepted effective treatments. Current research is mainly focus on blocking or delaying RGCs primary and/or secondary damage of optic nerve. " Qing Mang Yi Hao " is based on the previous experience of Wei Qiping, professor of the fourth generation of the Wei's ophthalmology department, and the effect is accurate in the application of decades of clinical practice. In this study , " Qing Mang Yi Hao "will be applied to experimental injury of RGCs cells and rat, and we will evaluate RGCs cell morphology and tissue pathology and the visual function of rat where the comprehensive evaluation index changes. This study use modern experiment science method to study the clinical prescription " Qing Mang Yi Hao ", It is the inheritance and development of famous traditional Chinese medicine experience, which may provide new theoretical guidance for clinical medication, at the same time lay a solid research foundation for the further explore of mechanism . This may also explore a new treatment for optic nerve injury.